Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia

References

• Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(24):5705–5717.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
   PubMed Web of Science ®Google Scholar
• Cairoli R, Beghini A, Turrini M, et al. Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta. Am J Hematol. 2013;88(7):594–600.
   PubMed Web of Science ®Google Scholar
• Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904–3911.
   PubMed Web of Science ®Google Scholar
• Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965–970.
   PubMed Web of Science ®Google Scholar
• Paschka P, Du J, Schlenk RF, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood. 2013;121(1):170–177.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115(12):2372–2379.
   PubMed Web of Science ®Google Scholar
• Krauth MT, Eder C, Alpermann T, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014;28(7):1449–1458.
   PubMed Web of Science ®Google Scholar
• Prébet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a Collaborative Study of the French CBF-AML Intergroup. J Clin Oncol. 2009;27(28):4747–4753.
   PubMed Web of Science ®Google Scholar
• Allen C, Hills RK, Lamb K, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013;27(9):1891–1901.
   PubMed Web of Science ®Google Scholar
• Yuichi I, Naomi K, Yoshiko A, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFβ-MYH11. Blood Adv. 2020;4(1):66–75.
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach T, Schoch C, et al. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006;107(10):3847–3853.
   PubMed Web of Science ®Google Scholar
• Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106(6):2113–2119.
   PubMed Web of Science ®Google Scholar
• Sang HP, Hyun JL, In SK, et al. Incidences and prognostic impact of c-KIT, WT1, CEBPA, and CBL mutations, and mutations associated with epigenetic modification in core binding factor acute myeloid leukemia: a multicenter study in a Korean population. Ann Lab Med. 2015;35:288–297.
   PubMed Web of Science ®Google Scholar
• Duployez N, Marceau RA, Boissel N, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127(20):2451–2459.
   PubMed Web of Science ®Google Scholar
• Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukemic haematopoietic stem cells in acute leukemia. Nature. 2014;506:328–333.
   PubMed Web of Science ®Google Scholar
• Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from next-generation sequencing data. Nucleic Acids Res. 2010;38(16):e164.
   PubMed Web of Science ®Google Scholar
• Hui W, Ying W, Chunlin Z, et al. Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population. J Hematol Oncol. 2018;11(1):18.
   PubMedGoogle Scholar
• Manara E, Bisio V, Masetti R, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia. 2014;28(5):1132–1134.
   PubMed Web of Science ®Google Scholar
• Yui S, Kurosawa S, Yamaguchi H, et al. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. Ann Hematol. 2017;96(10):1641–1652.
   PubMed Web of Science ®Google Scholar
• Duployez N, Micol JB, Boissel N, et al. Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). Leuk Lymphoma. 2016;57(1):199–200.
   PubMed Web of Science ®Google Scholar
• Micol JB, Duployez N, Boissel N, et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood. 2014;124(9):1445–1449.
   PubMed Web of Science ®Google Scholar
• Metzeler KH. ASXL genes and RUNX1: an intimate connection? Blood. 2014;124(9):1382–1383.
   PubMed Web of Science ®Google Scholar
• Nicolas D, Christophe W, Alice MR, et al. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Rev Hematol. 2015;8(1):43–56.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135(2):165–173.
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl Compr Canc Netw. 2012;10:984–1021.
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhao LJ, Wu CF, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA. 2011;108(6):2450–2455.
   PubMed Web of Science ®Google Scholar
• Zhao L, Melenhorst JJ, Alemu L, et al. KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. Blood. 2012;119(6):1511–1521.
   PubMed Web of Science ®Google Scholar
• Liu S, Wu LC, Pang J, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17(4):333–347.
   PubMed Web of Science ®Google Scholar
• Prieto-Conde MI, Jiménez C, García-Álvarez M, et al. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. Br J Haematol. 2020;189(4):718–730.
   PubMed Web of Science ®Google Scholar
• Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res. 2008;14(8):2249–2252.
   PubMed Web of Science ®Google Scholar
• Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res. 2007;67(15):7139–7146.
   PubMed Web of Science ®Google Scholar
• Chou FS, Wunderlich M, Griesinger A, et al. N-Ras (G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. Blood. 2011;117(7):2237–2240.
   PubMed Web of Science ®Google Scholar
• Raphael I, Nicolas D, Annette F, et al. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. Blood. 2018;132(2):187–196.
   PubMed Web of Science ®Google Scholar
• Cher CY, Leung GMK, Au CH, et al. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome. Blood Cancer J. 2016;6(7):e442.
   PubMedGoogle Scholar
• Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741–3750.
   PubMed Web of Science ®Google Scholar
• Yu G, Yin C, Wu F, et al. Gene mutation profile and risk stratification in AML1-ETO-positive acute myeloid leukemia based on next generation sequencing. Oncol Rep. 2019;42(6):2333–2344.
   PubMed Web of Science ®Google Scholar
• Liting X, John AP, Peter JM, et al. Nras G12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfb-SMMHC via activation of MEK/ERK axis. Blood. 2014;124(3):426–436.
   PubMed Web of Science ®Google Scholar
• Buet D, Gallais I, Lauret E, et al. Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia. Blood. 2012;119(18):4228–4241.
   PubMed Web of Science ®Google Scholar
• Awada H, Kishtagari A, Kuzmanovic T, et al. Impact and outcomes of RAS gene mutations in core binding factor acute myeloid leukemia. Blood. 2019;134(Suppl. 1):2720.
   Google Scholar